CAPA or corrective action is one of the most important aspects that the FDA focuses on to assess quality. Which is why it has been mentioned at least once in all warning letters issued by the FDA in 2017.
The current FDA scrutiny of CAPA plans has resulted in a number of roadblocks for Indian pharma companies which not only impact usual business but also result in exorbitant remediation costs.
In order to avoid these situations, we have collaborated with experts from US and Europe to put together a workshop that will help you build effective prevention and review strategies into your CAPA processes.
Dr. Nuala Calnan and Dr. José L. Toro will be in Hyderabad for Treffen Media’s “Deviation Management and CAPA” Workshop to help you with a robust plan for Effective Deviation and CAPA Management in a case study based practical workshop.